Építés alatt – nem éles oldal
Belépés
Résztvevőt keres2. fázis

A randomized, double-blind, placebo-controlled study to assess the effects of high concentration capsaicin patch (Qutenza) on neuropathic symptoms, nerve fibers, and microcirculation in painful diabetic peripheral neuropathy

A legfontosabb adatok

Ki végzi
Deutsche Diabetes Forschungsgesellschaft e.V.
Hol
Németország2 helyszín, 1 országbanVálassz országot a helyszínekhez
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
40 fő, tervezett
Kezdés
2026. júl. 29.
Várható befejezés
2028. márc. 31.
A vizsgálat típusa
Beavatkozással járó
A regiszteradat frissítve
2026. január 20.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with diabetes who have painful nerve damage in the feet or legs. It tests a capsaicin 8% skin patch (Qutenza) against a dummy patch.

Életkor
18-80 years
Nem
All sexes can join.
A betegség stádiuma
Diabetes for ≥1 year. Painful diabetic nerve damage (DSPN) for ≥6 months. Foot or ankle pain of ≥4 points on the NPRS pain scale, but an average daily pain below 9 points. Tingling or abnormal feelings in the legs for ≥6 months. Signs of nerve damage in the legs on exam or tests.
Korábbi kezelés
Glucose-lowering and pain treatment must be stable for 4 weeks before screening and stay unchanged during the trial. No Capsaicin 179 mg/8% patch in the last 6 months. No other pain treatment put on the painful skin areas in the last 3 months. No more than two pain medicines, no medium or high potency opioids and no electrical stimulation in the last 3 months.
Biomarker vagy leletérték
HbA1c <10% (86 mmol/mol) at screening. Skin nerve fiber density of at least 1 fiber/mm in a skin sample. Negative urine pregnancy test for women who could become pregnant.

A részvétel fő kizáró okai

  • Pregnant or breastfeeding women.
  • Foot ulcers in the last 6 months, or amputation of part of the leg.
  • Pain from other causes that cannot be told apart from the diabetic nerve pain.
  • Blood thinners (coumarins or heparin) at treatment dose, or other reasons a skin sample cannot be taken.
  • Cancer in the last 12 months (except basal cell skin cancer or low-grade prostate cancer), alcohol or drug use problems, or uncontrolled high blood pressure.

A regiszter feltételei, szó szerint

Mind a 31 feltétel megnézéseKevesebb

Ki vehet részt

  • Written informed consent signed and dated
  • Willingness to maintain current analgesic treatment unchanged during the course of the study
  • Ability and willingness to meet the study center visits and to undergo study procedures during the whole study duration
  • If applicable, willingness to take acceptable contraceptive measures by female participants in childbearing potential during the treatment phase
  • If applicable, negative urine pregnancy test by female participants in childbearing potential at screening
  • Diabetes mellitus according to the American Diabetes Association criteria (2017), lasting ≥1 year
  • Age: 18-80 years
  • Presence of painful diabetic sensorimotor polyneuropathy (DSPN) as judged by the investigator lasting ≥6 months
  • Presence of pain in the feet and/or ankle caused by painful DSPN as diagnosed by the investigator with an average or maximum NPRS of ≥4 points within 7 days before screening
  • Presence of dysesthesia or paresthesia in the lower extremity caused by DSPN as diagnosed by the investigator lasting ≥6 months
  • Presence of either i) neuropathic deficits in the lower extremity (reduced or absent achilles tendon reflexes, vibration sensation, temperature detection, pain perception, pressure sensation), ii) ≥1 abnormal nerve conduction study parameter in lower extremity peripheral nerves (reduced or not evoked peroneal or tibial motor nerve conduction velocity or sural sensory nerve conduction velocity or amplitude), iii) ≥1 abnormal quantitative sensory test at the lower extremity (temperature detection threshold, vibration perception threshold), or iv) reduced intraepidermal nerve fiber density at screening
  • HbA1c <10% at screening
  • If applicable, stable regimen of glucose-lowering and analgesic treatment for DSPN within 4 weeks prior to screening as judged by the investigator

Ki nem vehet részt

  • Treatment with coumarins or heparin in a therapeutic dose or other contraindications against obtaining skin biopsies at the distal calf
  • Participation in another clinical trial study within the last 3 months prior to screening
  • Neoplasms, except for basal cell carcinoma (basalioma) or low-grade prostate cancer within 12 months prior to screening
  • History of foot ulcers within the last 6 months prior to screening
  • Treatment with Capsaicin 179 mg/8% patch within the last 6 months prior to screening or with any other topical analgesic pain treatment on the areas affected by neuropathic pain due to painful DSPN within the last 3 months prior to screening
  • Concomitant analgesic treatment for painful DSPN with more than two substances, with medium or high potency opioids, or with electrical stimulation within the last 3 months prior to screening
  • Average daily pain level ≥9 points NPRS within 7 days before screening
  • Presence of pain caused by other conditions not clearly differentiated from pDPN as judged by the investigator
  • Currently active or history of alcohol use disorder (>24 units of alcohol per week) or other substance-use disorders as judged by the investigator within the last 5 years
  • Uncontrolled high blood pressure (DBP >95 mmHg and/or SBP >160 mmHg), unless clearly documented to be white-coat hypertension, at screening
  • Mental, psychiatric or other conditions compromising data collection or understanding of written or oral instructions during the study
  • Conditions that might interfere with the assessment of pDPN as judged by the investigator
  • History of amputations at the lower extremity excluding minor amputations due to traumatic events not related to diabetic foot syndrome
  • Contraindications, known allergy, or hypersensitivity to capsaicin or other ingredients of the study medication or local anesthetics
  • Intraepidermal nerve fiber density at screening <1 fiber/mm
  • Pregnant women or nursing mothers
  • Severe resting tachycardia (HR >110 bpm) at screening
  • Substantial change in analgesic treatment regimen during the study as judged by the investigator

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

To evaluate the efficacy of repeated treatment with capsaicin 8% cutaneous patch compared to placebo on skin innervation

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
A regiszteradat frissítve
2026. január 20.